Navigation Links
Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
Date:6/6/2012

FORT LAUDERDALE, Fla., June 6, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, reported today that production is complete on the first run of Azul Instant™, an all-natural male enhancement supplement for erectile dysfunction (ED) that works in 5 minutes and lasts up to 48 hours.

Nouveau Life began production of Azul Instant™ earlier this spring. Manufacturing is complete, and the product is currently being shipped to the warehouse. Nouveau Life anticipates online sales of Azul Instant™ to begin in the next two weeks.

In addition, Nouveau Life has released a complementary product to Azul Instant™ that can be taken daily to help the over 30 million men in the U.S. who suffer with ED. The new supplement Azul: Male Enhancer™ is designed to support a healthy libido in men. Regular use of the supplement Azul: Male Enhancer™ promotes being ready when it counts. Azul: Male Enhancer™ is available for purchase at www.nlpnaturals.com.

"It made sense to us that some men would prefer a daily supplement while some men would prefer a supplement that could be taken only when needed," stated Nouveau Life CEO Melissa Walker. "We are working behind the scenes to get Azul Instant™ on the market as quickly as possible. We know the market has been anxious for the supplement's arrival, as have we. It is the only all-natural ED supplement on the market that works in 5 minutes. In the meantime, we're proud to announce our daily ED supplement Azul: Male Enhancer."

With the addition of Azul: Male Enhancer™, Nouveau Life currently offers three all-natural supplement products. Nouveau Life's signature New Life Naturals™ line includes New Life Naturals: For Her Senses™ intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD) and New Life Naturals: For Your Weight Loss™, a Raspberry Ketone Formula with Acai designed to aid in safe weight loss for the 36% of Americans classified as obese. All of Nouveau Life's products can be purchased by visiting www.nlpnaturals.com.

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):